Next Article in Journal
Opposite Roles of Tra2β and SRSF9 in the v10 Exon Splicing of CD44
Next Article in Special Issue
Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy
Previous Article in Journal
9G TestTM Cancer/Lung: A Desirable Companion to LDCT for Lung Cancer Screening
 
 
Review

Transcriptional Control of Regulatory T Cells in Cancer: Toward Therapeutic Targeting?

Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Université Claude Bernard Lyon 1, Centre Léon Bérard, 69008 Lyon, France
*
Author to whom correspondence should be addressed.
These authors contributed equally to this paper.
Cancers 2020, 12(11), 3194; https://doi.org/10.3390/cancers12113194
Received: 9 October 2020 / Revised: 27 October 2020 / Accepted: 28 October 2020 / Published: 30 October 2020
(This article belongs to the Special Issue Regulatory T Cells in Tumor Environment)
Cancer outcomes are often indexed to the quality of the immune response to the tumor. Among immune cells, Foxp3+ regulatory T cells (Treg cells) are potent inhibitors of cancer immunity, and their presence within solid tumors is generally associated with a poor prognosis. Thus, understanding how Treg cell identity is controlled, is of utmost importance for the development of novel anti-cancer therapies. In this review, we summarize the current knowledge on the different intracellular pathways involved in the programming of Treg cell homeostasis and functions in cancer. We also highlight the therapeutic approaches aiming at targeting these regulators to enhance anti-tumor immunity.
Extensive research in the past decades has highlighted the tight link between immunity and cancer, leading to the development of immunotherapies that have revolutionized cancer care. However, only a fraction of patients display durable responses to these treatments, and a deeper understanding of the cellular and mechanisms orchestrating immune responses to tumors is mandatory for the discovery of novel therapeutic targets. Among the most scrutinized immune cells, Forkhead Box Protein P3 (Foxp3)+ Regulatory T cells (Treg cells) are central inhibitors of protective anti-tumor immunity. These tumor-promoting functions render Treg cells attractive immunotherapy targets, and multiple strategies are being developed to inhibit their recruitment, survival, and function in the tumor microenvironment. In this context, it is critical to decipher the complex and multi-layered molecular mechanisms that shape and stabilize the Treg cell transcriptome. Here, we provide a global view of the transcription factors, and their upstream signaling pathways, involved in the programming of Treg cell homeostasis and functions in cancer. We also evaluate the feasibility and safety of novel therapeutic approaches aiming at targeting specific transcriptional regulators. View Full-Text
Keywords: regulatory T cells; cancer; transcription; immunotherapy regulatory T cells; cancer; transcription; immunotherapy
Show Figures

Figure 1

MDPI and ACS Style

Stéphan, P.; Lautraite, R.; Voisin, A.; Grinberg-Bleyer, Y. Transcriptional Control of Regulatory T Cells in Cancer: Toward Therapeutic Targeting? Cancers 2020, 12, 3194. https://doi.org/10.3390/cancers12113194

AMA Style

Stéphan P, Lautraite R, Voisin A, Grinberg-Bleyer Y. Transcriptional Control of Regulatory T Cells in Cancer: Toward Therapeutic Targeting? Cancers. 2020; 12(11):3194. https://doi.org/10.3390/cancers12113194

Chicago/Turabian Style

Stéphan, Pierre, Raphaëlle Lautraite, Allison Voisin, and Yenkel Grinberg-Bleyer. 2020. "Transcriptional Control of Regulatory T Cells in Cancer: Toward Therapeutic Targeting?" Cancers 12, no. 11: 3194. https://doi.org/10.3390/cancers12113194

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop